Stocks · News reference
Assembly Biosciences Says Assembly Bio Eligible For Up To $280M In Milestones And Royalties Outside U.S.; GS-1179 Expected To Advance Into Phase 2 Trial For Genital Herpes By End Of 2026; Assembly Bio Expects Cash Runway Into 2029
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45
HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals
ResearchAndMarkets.com released a comprehensive analytical tool tracking CAR/TCR/TIL therapies in oncology, monitoring 870+ organizations and 2,370+ drugs across the pipeline. The tool provides competitive intelligence on leading developers including Gilead Sciences, Cellectis, MediGene, GenScript, and CARsgen Therapeutics, with 236 new therapies added in 2024/25 and over 1,700 BD&L contacts for partnership opportunities.